



358 South Main Street  
Burlington, NC 27215  
Telephone: (336) 584-5171

**FOR IMMEDIATE RELEASE**

**Contact:**

**Scott Frommer (investors) - 336-436-5076**

**[Investor@labcorp.com](mailto:Investor@labcorp.com)**

**Pattie Kushner (media) - 336-436-8263**

**[Media@labcorp.com](mailto:Media@labcorp.com)**

**Company Information: [www.labcorp.com](http://www.labcorp.com)**

**LABCORP IS SCHEDULED TO PRESENT AT THE  
2017 BARCLAYS GLOBAL HEALTHCARE CONFERENCE**

**Burlington, NC, March 6, 2017** — Laboratory Corporation of America<sup>®</sup> Holdings (LabCorp<sup>®</sup>) (NYSE: LH) today announced it will participate at the 2017 Barclays Global Healthcare Conference. LabCorp's presentation is planned for Wednesday, March 15, 2017 at 11:15 AM (ET).

A live audio webcast of the presentation will be available via the Company website at [www.labcorp.com](http://www.labcorp.com) and archived for replay.

**About LabCorp<sup>®</sup>**

Laboratory Corporation of America<sup>®</sup> Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to provide better care. With net revenue in excess of \$9 billion in 2016, LabCorp's 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit [www.labcorp.com](http://www.labcorp.com), and to learn more about Covance Drug Development, visit [www.covance.com](http://www.covance.com).

*This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the Company's Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.*

###